Oncomine Myeloid Panel [Only 29 Fusion Genes] Test
About Oncomine Myeloid Panel [Only 29 Fusion Genes] Test
| Field | Value |
|---|---|
| Also Known As | Oncomine Myeloid Fusion Panel, Myeloid Fusion Gene NGS Panel, OMP Fusion Test, RNA Fusion Panel for Myeloid Neoplasms |
| Sample Type | Bone marrow aspirate and peripheral blood (EDTA tube) |
| Fasting Required | No |
| Report Time | 30 days |
| Recommended For | Adults and children with suspected or confirmed myeloid malignancies; both genders |
| Price | Starting at ₹14,400 |
What Is an Oncomine Myeloid Panel [Only 29 Fusion Genes] Test?
The Oncomine myeloid panel [only 29 fusion genes] test is a specialised molecular test that uses next-generation sequencing (NGS) technology to detect abnormal fusion genes in blood cancer cells. Fusion genes form when two separate genes join together in an unusual way, driving uncontrolled cell growth. The test is prescribed for patients with suspected or confirmed myeloid malignancies, which are blood cancers arising from myeloid cells in the bone marrow. It is also known as the Oncomine myeloid fusion panel, myeloid fusion gene NGS panel, OMP fusion test, or RNA fusion panel for myeloid neoplasms. Samples collected include bone marrow aspirate and peripheral blood.
What Does an Oncomine Myeloid Panel [Only 29 Fusion Genes] Test Measure?
The Oncomine myeloid panel [only 29 fusion genes] test analyses RNA extracted from bone marrow or blood to detect 29 specific fusion genes associated with myeloid blood cancers. Identifying which fusion gene is present helps doctors classify the disease, assess risk, and select appropriate treatment.
The 29 gene targets covered by this panel are listed below:
| Gene | Relevance |
|---|---|
| ABL1 | Associated with chronic myeloid leukaemia (CML) via BCR-ABL1 fusion |
| ALK | Fusion partner in certain myeloid rearrangements |
| AKT3 | Involved in cell survival signalling pathways |
| AXL | Linked to myeloid cell proliferation |
| BRAF | Associated with myeloproliferative conditions |
| EGFR | Receptor kinase involved in cancer cell growth |
| ERBB2 | Growth factor receptor relevant in some myeloid subtypes |
| ERG | Transcription factor involved in leukaemia |
| ETV1 | ETS family transcription factor |
| ETV4 | ETS family transcription factor |
| ETV5 | ETS family transcription factor |
| FGFR1 | Fibroblast growth factor receptor; found in myeloid/lymphoid neoplasms |
| FGFR2 | Fibroblast growth factor receptor rearrangements |
| FGFR3 | Fibroblast growth factor receptor rearrangements |
| MET | Receptor tyrosine kinase involved in myeloid disorders |
| NTRK1 | Neurotrophic receptor kinase fusion target |
| NTRK2 | Neurotrophic receptor kinase fusion target |
| NTRK3 | Neurotrophic receptor kinase fusion target |
| PDGFRA | Associated with myeloid/lymphoid neoplasms with eosinophilia |
| PPARG | Nuclear receptor involved in myeloid differentiation |
| RAF1 | Kinase involved in cell proliferation signalling |
| RET | Receptor tyrosine kinase fusion target |
| ROS1 | Receptor tyrosine kinase involved in myeloid rearrangements |
Why Is an Oncomine Myeloid Panel [Only 29 Fusion Genes] Test Done?
Doctors order this test when a patient shows signs of a myeloid blood disorder and detailed genetic information is needed for accurate diagnosis, risk classification, and treatment planning.
Common Symptoms That May Require This Test
The following symptoms may prompt a doctor to request this test:
- Persistent fatigue and weakness without a clear cause
- Unexplained fever or recurrent infections
- Unusual or easy bleeding and bruising
- Bone pain or discomfort
- Unexplained weight loss
- Night sweats
- Enlarged spleen causing discomfort in the abdomen
Conditions This Test Can Help Detect
This panel can help identify a range of myeloid blood cancers and related conditions:
- Chronic myeloid leukaemia (CML), where the BCR-ABL1 fusion is present in over 90% of cases
- Acute promyelocytic leukaemia (APL), defined by the PML-RARA fusion
- Core binding factor AML, involving RUNX1-RUNX1T1 or CBFB-MYH11 fusions
- Myelodysplastic syndrome (MDS) with specific genetic features
- Myeloproliferative neoplasms (MPN) with gene rearrangements
- Chronic myelomonocytic leukaemia (CMML) and juvenile myelomonocytic leukaemia (JMML)
- Aggressive leukaemia subtypes associated with KMT2A and NUP98 rearrangements
Oncomine Myeloid Panel [Only 29 Fusion Genes] Test for Chronic Disease Monitoring
Fusion genes act as reliable markers for tracking disease activity over time. This test may be repeated during treatment to assess how well therapy is working, to check for signs of disease returning, and to monitor progression in patients with a known fusion-positive myeloid malignancy. Regular monitoring allows oncologists to adjust treatment plans based on current disease status.
How to Prepare and What to Expect
No special preparation is required before this test, but there are a few practical points to keep in mind.
Do You Need to Fast?
No fasting is required for this test. You can eat and drink normally before your appointment. Always follow specific instructions provided by the doctor or laboratory at the time of booking.
Practical Tips Before Your Test
The following steps will help your appointment go smoothly:
- Bring a detailed clinical history, including your symptoms, previous test results, and family history, as this is required for the test
- Inform your doctor about all medications you are currently taking, particularly anticoagulants (blood thinners)
- Wear comfortable, loose-fitting clothing that allows easy access to the arm or hip area
Step-by-Step Procedure
This test requires a bone marrow sample and a peripheral blood sample. The collection process for each is described below:
Bone Marrow Collection
- You will be asked to lie on your side or stomach on an examination table.
- The doctor applies a local anaesthetic to the skin and underlying area, usually over the hip bone.
- A thin needle is carefully inserted into the bone to withdraw a small amount of bone marrow fluid (bone marrow aspiration).
- The sample is collected in a lavender-top EDTA tube and labelled with your details.
- The site is cleaned, and a small dressing is applied. The procedure typically takes 15 to 30 minutes.
- The sample is refrigerated and dispatched to the laboratory, ideally within 24 hours.
- In the laboratory, RNA is extracted and analysed using next-generation sequencing (NGS) to detect fusion genes.
Peripheral Blood Collection
- A trained phlebotomist cleans the inside of your elbow with an antiseptic.
- A small needle is used to draw 3 ml of blood from a vein in your arm into a lavender-top EDTA tube.
- The needle is removed, and a cotton swab or bandage is applied to stop any minor bleeding.
- The sample is stored under refrigeration and sent to the laboratory promptly.
Factors That Can Affect Accuracy
Several factors can influence how reliable the results are:
- Poor RNA quality due to delays in sample processing or improper storage
- A low number of cancer cells (blast cells) in the collected sample
- Prior treatment, which may alter the detectable fusion gene profile
- Inadequate sample volume collected at the time of aspiration
- Technical handling between collection and laboratory processing
Understanding Your Oncomine Myeloid Panel [Only 29 Fusion Genes] Test Results
Results from this test are qualitative, indicating whether a specific fusion gene was detected. A haematologist or oncologist should review all results alongside clinical findings, cell morphology (how the cells look under a microscope), immunophenotyping, and other genetic tests. The table below shows a general interpretation of results:
| Parameter | Normal Result |
|---|---|
| Fusion genes (all 29 targets) | Not detected (Negative) |
A negative result means none of the 29 fusion genes was identified. This does not rule out myeloid malignancy, as some cancers are driven by other genetic changes such as point mutations rather than fusions. A positive result identifies the specific fusion gene(s) present and carries important information about cancer subtype, prognosis, and treatment options.
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain situations may affect how results are interpreted:
- A low blast count (proportion of cancer cells) in the sample can reduce the test's ability to detect fusions, particularly in early-stage disease.
- Peripheral blood samples have been shown to reliably classify and monitor myeloid neoplasms even without high numbers of circulating blast cells, making them a viable alternative when bone marrow collection is not possible.
- Samples with degraded RNA, often due to delayed transport or improper refrigeration, may yield inconclusive results and require recollection.
How to Maintain Healthy Levels
This is a diagnostic and monitoring test for blood cancers rather than a routine wellness check. There are no specific lifestyle measures that alter fusion gene status.
- Attend all follow-up appointments with your haematologist or oncologist as scheduled
- Keep copies of all previous test results to help your doctor track changes over time
- Prompt reporting of new or worsening symptoms allows timely repeat testing if needed
Lupin Diagnostics Oncomine Myeloid Panel [Only 29 Fusion Genes] Test Price
The Oncomine myeloid panel [only 29 fusion genes] test cost starts at ₹14,400 at Lupin Diagnostics. This test requires a hospital visit; home collection is not available due to the specialised nature of bone marrow aspiration and the RNA preservation requirements for peripheral blood samples. The table below shows indicative prices across major Indian cities:
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 14400 |
| Pune | 14400 |
| Bangalore | 14400 |
| Chennai | 14400 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps for the Oncomine myeloid panel [only 29 fusion genes] test online booking:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
This test detects 29 specific fusion genes associated with myeloid blood cancers. Doctors use the results to diagnose the exact type of myeloid malignancy, assess prognosis, and select targeted treatments. It is a key part of the molecular workup for conditions such as leukaemia and myelodysplastic syndromes.
Fusion genes are found in approximately 30 to 40% of patients with AML and play a central role in defining clinically relevant cancer subtypes. Identifying them guides risk stratification and informs treatment decisions, as certain fusions indicate favourable outcomes while others suggest more aggressive disease requiring intensive therapy.
Bone marrow aspirate collected in a lavender-top EDTA tube is preferred for initial diagnosis. Peripheral blood in the same tube type is an acceptable alternative. Both samples must be refrigerated and sent to the laboratory promptly to preserve RNA quality.
Lupin Diagnostics delivers results within 30 days from the date of sample collection. The test results are delivered directly via email or WhatsApp once they are ready.
No. The Oncomine myeloid panel [only 29 fusion genes] test home collection is not available. Bone marrow aspiration must be performed in a clinical setting by a trained specialist, and blood samples require careful handling for RNA preservation immediately after collection.
Not necessarily. A negative result means none of the 29 specific fusion genes were detected. Some myeloid malignancies are caused by point mutations or other genetic changes not covered by a fusion panel. Your doctor may request additional molecular tests to fully evaluate your condition.
No. The Oncomine myeloid panel complements conventional methods such as karyotyping (chromosome analysis) and FISH (fluorescence in situ hybridisation) rather than replacing them. RNA-based fusion testing can detect clinically important events that chromosome analysis alone may miss. Your doctor will determine which combination of tests is appropriate for your case.
Oncomine Myeloid Panel [Only 29 Fusion Genes] Test
